Vancouver, Canada

Kevin Jepson

USPTO Granted Patents = 3 

Average Co-Inventor Count = 24.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
3 patents (USPTO):

Title: Kevin Jepson: Innovator in Anti-Coronavirus Antibodies

Introduction

Kevin Jepson is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies aimed at combating coronavirus-related diseases. With a total of 3 patents, his work is pivotal in the ongoing fight against viral infections.

Latest Patents

Kevin Jepson's latest patents focus on anti-coronavirus antibodies and their methods of use. These antibodies are designed to bind to the spike proteins of SARS-CoV and SARS-CoV-2. His innovations include methods for treating or preventing conditions associated with SARS or COVID-19, as well as techniques for detecting these viruses. This work is crucial for advancing therapeutic options and diagnostic tools in the face of global health challenges.

Career Highlights

Throughout his career, Kevin has worked with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and Abcellera Biologics Inc. His experience in these institutions has allowed him to contribute to groundbreaking research and development in the field of immunology.

Collaborations

Kevin Jepson has collaborated with talented individuals in his field, including Kathryn Westendorf and Stefanie Zentelis. These partnerships have fostered innovation and have been instrumental in the advancement of his research projects.

Conclusion

Kevin Jepson's work in developing anti-coronavirus antibodies showcases his commitment to addressing critical health issues. His patents and collaborations reflect a dedication to scientific advancement and public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…